Epidiolex-treated LGS Boy Has No Seizures, Near-normal EEG Pattern, Case Study Reports 

Epidiolex-treated LGS Boy Has No Seizures, Near-normal EEG Pattern, Case Study Reports 
0
(0)

Adding Epidiolex, an oral cannabidiol medication, to other treatments successfully stopped epileptic seizures in a boy with Lennox-Gastaut syndrome (LGS), resulting in nearly normal electrical activity in the brain, a real-world case study reported.

The case study, “Effect of Cannabinoids on Electroencephalography of a Child with Lennox–Gastaut Syndrome,” was published in the Journal of Neurosciences in Rural Practice.

Developed by GW Pharmaceuticals, Epidiolex is a cannabidiol (CBD) solution, extracted from the cannabis plant, that is approved to treat seizures in patients with LGS, ages 1 and older. Clinical trials demonstrated that Epidiolex reduced the frequency of attacks in LGS, either alone or as an add-on treatment.

Now, an investigator at the Arnold Palmer Hospital, in Florida, described the case of a boy with LGS of unknown cause who was successfully treated with Epidiolex with dramatic results. As such, an electroencephalography or EEG scan — which detects electrical activity in the brain — was done to reveal the impact of Epidiolex on his brain’s electrical patterns. 

“No studies have been published that document the effect of [Epidiolex] on electroencephalography (EEG) yet,” the researcher wrote. “It is not yet known whether [Epidiolex] changes EEG and how it improves as the seizures get better in those who respond to the treatment with reduction in seizures.”

At age 9, this boy had absence seizures, which presented as lapses in awareness. An EEG scan showed patterns typically seen in those with this type of seizure. 

Instead of medications, his parents partially controlled the boy’s seizures with a self-formulated ketogenic diet — a high-fat, low-carbohydrate diet that alters energy metabolism in the brain.

The child had his first generalized tonic-clonic seizure (GTCS) at age 10, which was characterized by a loss of consciousness, muscle stiffening, and jerking movements. At that time, EEG scans showed a transition into a typical LGS pattern. 

Along with the keto diet, the boy was started on the anticonvulsant therapy levetiracetam. Still, his seizures continued with daily absence seizures and infrequent GTCS, and he was twice hospitalized with multiple episodes. 

He was given the anti-seizure medicine phenytoin along with levetiracetam, which controlled his GTCSs. He also received high-dose steroids for five days, and the ketogenic diet was stopped. Despite these measures controlling most seizures, the same LGS-like EEG pattern persisted.

Some remaining absence seizures were controlled with the addition of Epidiolex, at a daily dose of 5 mg/kg of body weight, while maintaining phenytoin.

However, at the age of 10.5, the boy started having drop attacks (atonic seizures), or sudden spontaneous falls while standing or walking. The Epidiolex dose was increased to 11 mg/kg per day (total 350 mg/day), and he continued phenytoin. 

The boy eventually became seizure-free and did not experience further seizures while receiving Epidiolex and phenytoin. He retuned to regular school classes and is learning at an age-appropriate level. 

An EEG assessment five months after starting Epidiolex showed a near-normal pattern that was sustained with only mild, infrequent, epileptic-type patterns. Further MRI scans also were normal, and a genetic screen did not detect any disease-causing mutations. 

“In conclusion, [Epidiolex] improves EEG patterns besides improving seizure control as our case demonstrates,” the author wrote. “Early intervention besides age of onset of LGS might influence outcome.”

The researcher said further investigation was needed into Epidiolex’s impact on EEG patterns.

“Larger studies and analysis of EEG in patients with unknown/genetic [cause] of LGS will be needed to confirm the finding,” he added. 

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Total Posts: 0
Ana de Barros, PhD Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Latest Posts
  • Epidiolex, case study, stopped seizures
  • Inovelon/Banzel study
  • lithium toxicity case study
  • Epidyolex available in Scotland

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *